A judge has put a halt to President Trump’s requirement for drug prices in television ads.
Julius Hobson
A federal judge stopped President Trump’s drug price television ad requirement.
U.S. District Judge Amit Mehta said that drug makers will not have to reveal their prices in television ads.
HHS Secretary Alex Azar announced the final rule from CMS in May, which requires direct-to-consumer television advertisements for prescription drugs covered by Medicare or Medicaid to include the Wholesale Acquisition Cost-if that price is equal to or greater than $35 for a month’s supply or the usual course of therapy, according toFormularyWatch.
“It was always my opinion that HHS/CMS did not have the authority to require drug companies to post prices in their direct-to-consumer advertisements,” says Julius Hobson, Jr., senior policy advisor, at Polsinelli, a firm with offices in Washington, D.C.
Related article: New Drug Pricing Act Could Change Drug Pricing
“Judge Mehta’s opinion rightly points out there is no express authorization in federal statues providing the HHS the authority to require price disclosure in ads,” Hobson says. “Further, as the judge also points out, the drug companies are not direct participants in Medicare and Medicaid programs. An attempt to force price transparency was a stretch. Down the road, this opinion, if upheld on appeal, will place more pressure on Congress to enact legislation to require some type of drug pricing transparency.”
James Mather, senior pharma analyst at GlobalData, a data and analytics company, expressed concerns about the new policy back in May.
A drug’s list price does not translate directly into the ‘true’ price of a drug, Mather said in a GlobalData release. “Drug makers often bundle their brands together when negotiating, meaning the individual drug list prices can be almost meaningless in these cases,” he said.
Optimize Your Healthcare Payments with Optum Financial
April 29th 2025Discover how Optum Financial is revolutionizing healthcare payments in our latest whitepaper. Learn how transitioning to electronic payments can reduce administrative costs, streamline claims processing and enhance security.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Healthcare hasn't been a priority of the second Trump administration so far, panelists at the Asembia agreed. Medicaid may loom large, though, as the administration and congressional Republicans look for ways to slash government spending as a way of offsetting major tax cuts.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
What 5 Managed Care Trends Experts Say You’re Not Watching Closely Enough
April 29th 2025Managed Healthcare Executive asked several experts in healthcare and managed care to share the trends they think the industry is overlooking. From rising costs and data challenges to shifts in how care is delivered, these are the issues that could have a major impact — and deserve a closer look.
Read More